Binding of 125I-bFGF to Rat Aortic Smooth Muscle Cells

Effect of Natural and Chemically Modified Heparins and Heparan Sulfates
  • Laura Giorgini
  • Annamaria Naggi
  • Giancarlo Ghiselli


The proliferation of smooth muscle cells (SMC) in the arterial wall is a key event in the development of atherosclerosis. The locally formed mitogen bFGF is likely to play an important role in initiating and in maintaining the SMC proliferative state. A distinguishing characteristic of bFGF is its strong interaction with the sulfated glycosaminoglycans. In this study the ability of a series of chemically modified heparins and heparan sulfates to compete with the cell surface glycosaminoglycans for 125I-bFGF binding has been investigated. Rat aortic SMC between the 8th and the 18th passage were used. Within the heparin series the order of potency was: Heparin, 6-O-desulfated > 2-O desulfated >> N-acetylated. However, when the activity of the series of heparins for the inhibition of cell growth was assessed, 6-O sulfation was as important as 2-O and N- sulfation. Heparan sulfates gave comparable results. The data presented are consistent with the concepts that: 1) specific structural features are involved in the interaction of SMC glycosaminoglycans with 125I-bFGF, and 2) antimitogenic activity of heparin has structural requirements different than those for bFGF binding.


Heparan Sulfate Basic Fibroblast Growth Factor Smooth Muscle Cell Proliferation Sulfated Glycosaminoglycan Sulfated Glucosamine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Campbell, G.R., Chamley-Campbell J.H.: The cellular pathobiology of atherosclerosis. Pathology 1981; 13, 423–440PubMedCrossRefGoogle Scholar
  2. 2.
    Ross, R.: Atherosclerosis: A problem of the biology of arterial wall cells and their interactions with blood components. Arteriosclerosis 1981; 1, 293–311PubMedCrossRefGoogle Scholar
  3. 3.
    Campbell J.H., Popadynec, L., Nestel, P.J., Campbell, R.: Lipid accumulation in arterial smooth muscle cells. Influence of phenotype. 1983; 47, 279–295Google Scholar
  4. 4.
    Bihara-Varga, M., Camejo, G., Horn, M.C., Szabo, D., Lopez, F., and Gruber, E.: Structure of low-density lipoprotein in complexes formed with arterial matrix components. International J. Biol. Macromol. 1983; 5, 59–63CrossRefGoogle Scholar
  5. 5.
    Ross, R.: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993;362:801–809.PubMedCrossRefGoogle Scholar
  6. 6.
    Basilico, C., and Moscatelli, D.: The FGF family of growth factors and oncogenes. Adv. Cancer Res. 1992; 59, 115–165CrossRefGoogle Scholar
  7. 7.
    Yamaguchi, Y.: Proteoglycan-growth factor interactions. Trends Glycosci. Glycotechnol. 1993; 5, 428–437CrossRefGoogle Scholar
  8. 8.
    Klagsbrun, M., and Baird, A.: A dual receptor system is required for basic fibroblast growth factor activity. Cell 1991; 67, 229–231PubMedCrossRefGoogle Scholar
  9. 9.
    Moscatelli, D.: High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J. Cell. Physiol. 1987; 131, 123–130PubMedCrossRefGoogle Scholar
  10. 10.
    Yayon, A., Klagsbrun, M., Esko, J.D., Leder, P., and Ornitz, D.M.: Cell surface heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991; 64, 841–848PubMedCrossRefGoogle Scholar
  11. 11.
    Neufeld, G., and Gospodorowicz, D.: The identification and partial characterization of the fibroblast growth factor receptor of baby hamster cells. J. Biol. Chem. 1985; 260, 13860–13868PubMedGoogle Scholar
  12. 12.
    Gigli, M., Consonni, A., Ghiselli, G., Rizzo, V., Naggi, A., and Torri, G.: Heparin binding to human low density lipoproteins: Dependence on heparin sulfation degree and chain length. Biochemistry 1992; 31, 5996–6003PubMedCrossRefGoogle Scholar
  13. 13.
    Clowes, A.W., and Karnowsky, M.J.: Suppression by heparin of smooth muscle proliferation in injured arteries. Nature, 1977;265:625–626.PubMedCrossRefGoogle Scholar
  14. 14.
    Currier, J.W., Pow, T.K., Haudenschild, C.C., Minihan, A.C., and Faxon, D.P.: Low molecular weight heparin (enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit. J. Am. Coll. Cardiol. 1991;17:118B–124B.PubMedCrossRefGoogle Scholar
  15. 15.
    Franklin, S.M., and Faxon, D.P.: Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Coronary Artery Disease, 1993;4:232–242.PubMedCrossRefGoogle Scholar
  16. 16.
    Rapraeger, C., Krufka, A., and Olwin, B.B.: Requirement of heparan sulfate bFGF mediated fibroblast growth and myoblast differentitaion. Science 1991; 252, 1705–1708PubMedCrossRefGoogle Scholar
  17. 17.
    Ornitz, D.M., Yayon, A., Flanagan, J.G., Svahn, CM., Levi, E., and Leder, P.: Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. 1992; Mol. Cell Biol. 12, 240–247Google Scholar
  18. 18.
    Roghani, M., Mansukhani, A., Dell’Era, P., Bellosta, P., Basilico, C., Rifkin, D.B., and Moscatelli, D.: Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J. Biol. Chem. 1994; 269, 3976–3984.PubMedGoogle Scholar
  19. 19.
    Maccarana, M., Casu, B., and Lindahl, U.: Minimal sequence in Heparin/Heparan Sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 1993; 268, 23898–23905PubMedGoogle Scholar
  20. 20.
    Ishihara, M., Shaklee, P.N., Yang, Z., Liang, W., Wei, Z., Stack, R.J., and Holme, K.: Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factor. Glycobiology, 1994 4, 451–458PubMedCrossRefGoogle Scholar
  21. 21.
    Guimond, S., Maccarana, M., Olwin, B.B., Lindahl, U., and Rapraeger, A.C.: Activating and inhibitory sequences for FGF-2 (basic FGF). J. Biol. Chem. 1993; 268, 23906–23914PubMedGoogle Scholar
  22. 22.
    Castellot, J.J., Wong, K., Herman, B., Hoover, R.L., Albertini, D.F., Wright, T.D., Caleb, B.L., and Karnovsky, M.G.: Binding and internalization of heparin by smooth muscle cells. J. Cellular Physiol. 1985; 124, 13–19CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1996

Authors and Affiliations

  • Laura Giorgini
    • 1
  • Annamaria Naggi
    • 2
  • Giancarlo Ghiselli
    • 1
  1. 1.Cardiovascular DepartmentFarmitalia Carlo ErbaMilanItaly
  2. 2.Istituto di Chimica e Biochimica “G. Ronzoni”MilanItaly

Personalised recommendations